Rheumatoid arthritis
Conditions
Interventions
Sponsors
Nanfang Hospital, Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Voluntarily sign the informed consent form; Male and female patients aged >= 18 years and < 75 years 3. After receiving ADA treatment (40mg, q2w, subcutaneous) for more than 6 months but less than 2 years, it can be combined with other conventional synthetic antirheumatic drugs for improving the condition (csDMARDs), with a stable dose for more than 4 weeks. 4. When screening, if the subjects are taking non-steroidal anti-inflammatory and analgesic drugs (NSAIDS), the dosage should remain stable for at least 4 weeks. 5. If the subjects are taking oral corticosteroids during screening, the dose (equivalent to the dose of prednisone) must be kept stable at less than 10mg per day for at least 4 weeks.
Exclusion criteria
Exclusion criteria: 1. Those with a history of severe diseases of vital organs such as the heart, liver, and kidneys, as well as blood and endocrine system disorders; 2.Have received treatment with other biological agents within 6 months; 3. Pregnant and lactating women; 4. Those who are currently in the period of acute or chronic infection, or have a history of active tuberculosis; 5. Patients with malignant tumors; 6. Patients with mental illness or intellectual disability who have difficulty completing the content of the assessment questionnaire. 7. The researcher judged that it was not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rheumatoid arthritis related indicators;Anti-adalimumab antibody concentration;DAS28 score;Adalimumab concentration;Methotrexate and methotrexate polyglutamate concentrations;HAQ score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver and kidney function; | — |
Countries
China
Contacts
Public ContactLiqian Mo
Nanfang Hospital, Southern Medical University
Outcome results
None listed